Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

INAB
IN8bio, Inc. Common Stock
stock NASDAQ

At Close
Jul 14, 2025 3:59:30 PM EDT
2.22USD-3.057%(-0.07)141,493
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 11, 2025 9:28:30 AM EDT
2.38USD+3.974%(+0.09)0
After-hours
Jul 14, 2025 4:02:30 PM EDT
2.20USD-0.901%(-0.02)968
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
09:05AM EST  B. Riley Securities Maintains Buy on IN8bio, Lowers Price Target to $9   Benzinga
Jan 10, 2022
07:00AM EST  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present at four upcoming virtual investor conferences in January.   GlobeNewswire Inc
Jan 6, 2022
07:06AM EST  IN8bio Announces Clinical Updates From The Phase 1 Clinical Trial Of Its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme   Benzinga
07:00AM EST  -- INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort   GlobeNewswire Inc
Dec 16, 2021
07:08AM EST  IN8bio Provides Update From The Ongoing Phase 1 Clinical Trial Of Its Allogeneic Gamma-Delta T Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant   Benzinga
07:00AM EST  IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of   GlobeNewswire Inc
Dec 9, 2021
09:58PM EST  IN8bio Promotes Kate Rochlin, Ph.D. To Chief Operating Officer   Benzinga
04:30PM EST  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation.   GlobeNewswire Inc
Nov 16, 2021
07:27AM EST  IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer   Benzinga
07:00AM EST  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the appointment of Trishna Goswami, M.D. as Chief Medical Officer.   GlobeNewswire Inc
Nov 11, 2021
07:06AM EST  IN8bio To Present Preclinical Data On The Potential For Gamma-Delta T-cell Therapy Combinations With PARP And Checkpoint Inhibitors In Solid Tumors   Benzinga
07:00AM EST  IN8bio to Present Preclinical Data on the Potential for   GlobeNewswire Inc
Nov 10, 2021
06:33PM EST  IN8bio, Inc. - Common Stock Q3 EPS $(0.25) Up From $(0.60) YoY   Benzinga
Nov 4, 2021
08:00AM EDT  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November.   GlobeNewswire Inc
Oct 27, 2021
07:00AM EDT  Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 4, 2021
04:19PM EDT  IN8bio To Present At BioFuture 2021 And Advanced Therapies Congress & Expo 2021 Oct. 5   Benzinga
04:15PM EDT  IN8bio to Present at BioFuture 2021 and Advanced Therapies   GlobeNewswire Inc
Sep 13, 2021
06:11AM EDT  A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises 1%   Benzinga
Sep 10, 2021
07:36PM EDT  IN8bio Q2 2021 EPS $(1.00)   Benzinga
04:15PM EDT  -- First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100 -- Data presentations made at ASCO and AACR -- $40M initial public offering (IPO) in August 2021 to fund continuing operations   GlobeNewswire Inc
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 30, 2021
07:00AM EDT  IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H   GlobeNewswire Inc
Aug 24, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021   Benzinga
09:43AM EDT  Mizuho Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $12   Benzinga
Aug 23, 2021
10:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021   Benzinga
05:17AM EDT  B. Riley Securities Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $19   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:05AM EDT  IN8bio Completes Dosing Of First Cohort In Phase 1 Clinical Trial With Allogeneic Gamma Delta T-Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant   Benzinga
08:00AM EDT  The first cohort has completed dosing with IN8bios donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date   GlobeNewswire Inc
Aug 4, 2021
08:00AM EDT  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors.   GlobeNewswire Inc
Jul 30, 2021
11:36AM EDT  IN8bio Shares Open For Trade At $10; IPO Priced At $10/Share   Benzinga
09:20AM EDT  IN8bio Shares Will Open For Quote At 11:25 a.m. EDT, Expected To Open For Trade After 11:35 a.m. EDT; IPO Priced At $10/Share   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:00AM EDT  IN8bio Announces Pricing of Initial Public Offering   GlobeNewswire Inc
Jul 27, 2021
11:13AM EDT  The IPO Market Is On Fire With Another Record Week Ahead   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC